Tuesday, January 09, 2018 8:24:36 AM
Recent INCY News
- Incyte präsentiert neue Phase-3-Daten zu Tafasitamab auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) • Business Wire • 04/22/2026 10:41:00 AM
- Incyte présente de nouvelles données de phase III sur le tafasitamab au congrès annuel 2026 de l’American Society of Clinical Oncology (ASCO) • Business Wire • 04/22/2026 10:40:00 AM
- インサイト、2026年米国臨床腫瘍学会(ASCO)年次総会でタファシタマブの第3相臨床試験の最新データを発表 • Business Wire • 04/22/2026 10:39:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 08:09:07 PM
- Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting • Business Wire • 04/21/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:13:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:12:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:12:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/17/2026 08:07:44 PM
- Incyte to Report First Quarter Financial Results • Business Wire • 04/09/2026 12:00:00 PM
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:10:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:09:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:35:18 PM
- Incyte annonce de nouvelles données positives de dernière minute portant sur 54 semaines concernant le povorcitinib dans le traitement de l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD) • Business Wire • 03/29/2026 05:51:00 PM
- Incyte präsentiert neue positive 54-Wochen-Daten zu Povorcitinib bei Hidradenitis suppurativa auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) • Business Wire • 03/29/2026 05:10:00 PM
- Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting • Business Wire • 03/28/2026 07:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 08:13:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:38:39 PM
- Incyte annonce des nominations au sein de sa haute direction • Business Wire • 03/25/2026 08:17:00 PM
- Incyte verkündet Ernennung von Führungspersonal • Business Wire • 03/25/2026 07:57:00 PM
- Incyte Announces Executive Leadership Appointments • Business Wire • 03/25/2026 01:00:00 PM
- Incyte wird auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) die neuesten Daten aus der Hidradenitis suppurativa-Forschung vorstellen • Business Wire • 03/20/2026 11:42:00 PM
- Incyte présentera des données de dernière minute sur l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD) • Business Wire • 03/20/2026 11:42:00 PM
- Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting • Business Wire • 03/20/2026 02:00:00 PM
